

2023 Virginia General Assembly Session: HB 2200 Opportunities and Next Steps



Joel Andrus




Allison Rollins, MSc



Representing:

Blue Ridge Cancer Care
Shenandoah Oncology
Virginia Cancer Specialists
Virginia Oncology Associates



Inspiration for HB 2200: BPOL Liability in Community Oncology

Here Are Some Typical Features of the Average Locality's BPOL Tax Rates for Health Care Services Provided in the Community Setting:

- Taxes are charged at the Professional rate (highest possible rate)
- Taxes only imposed on for-profit businesses making \$100,000+ annually in gross receipts
- Rates are set at either a flat fee or at a percentage of overall gross receipts- it varies by locality.



There is only one hospital in Virginia that does not have “Non-Profit” status. BPOL is a tax imposed only on the community oncology site of service.



of Virginia localities impose some form of BPOL tax.

Virginia has **95 counties** and **38 independent cities** that are all granted the authority by the state to impose their own BPOL tax rates.



***Professional Service BPOL tax rates** that are imposed as a percentage typically range between \$0.10 to \$0.58 per \$100 of Gross Receipts Annually.*



Original Intent of HB 2200's Predecessor: 2022 HB 698

This bill requested the state to grant localities the flexibility to determine potential BPOL tax exemptions for individual entities at their discretion.



The ability for a given community oncology practice to request BPOL tax flexibilities from the localities they serve.



The Evolution of 2022 HB 698 to 2023 HB 2200



HB 698 Referred to Study

HB 698 was referred to Interim study where we collaborated with stakeholders VML and VACO to look into BPOL relief for physician administered medications.

2022 Interim BPOL Study Committee

The study group resolved to narrow the bill to physician administered anti-cancer medications reimbursed by government payers.

HB 2200 As Passed the House

The Chair of the House Finance Committee refiled HB 698 as HB 2200 with new language exempting infused anti-cancer medications reimbursed by Medicaid, Medicare, and TRICARE from BPOL.



Final Version of 2023 VA HB 2200


Creates An Interim Working Group on State Policy Barriers to Access to Care for Infusion Anti-Cancer Drugs in the Community Oncology Setting:

Working Group Goal:

*Analyze and review **current reimbursement and operational challenges** for medical practices that administer anti-cancer drugs in an in-office setting to patients whose costs for such treatment are paid for by Medicare, Medicaid, or TRICARE.*



Regional Impact



Working Group Membership

Convened by the Secretary of Health and Human Resources in collaboration with the Department of Health.

Other stakeholders include:

- Medical Society of Virginia
- Virginia Association of Hematologists and Oncologists
- Virginia Association of Counties
- Virginia Municipal League
- Other Stakeholders as Appropriate



Timeline for Working Group Activity



Timeline:



**VAHO 2023
Spring
Conference**

May 11- 13, '23



**Working Group
Interim Meetings**

June – Sept. '23



**Final Deadline
for Interim
Meetings**

Oct. 1, '23



**Final Report
Submission**

Nov. 15, '23




Guided Discussion on Potential Working Group Priorities



Transportation Benefits
in Medicaid Managed
Care/ Medicare
Supplemental Plans

Medicaid Physician Fee
Schedules V. Hospital
Fee Schedules

Medicaid
Reimbursement for Anti-
Cancer Drugs



Workforce Shortage
Stimulus Policies

Health Care Service Taxes

BPOL Tax Flexibility

Reimbursement for
Clinical Services
Performed by Non-
Physician Providers

